Cargando…

Molecular mechanisms underlying the pilsicainide-induced stabilization of hERG proteins in transfected mammalian cells

BACKGROUND: Pilsicainide, classified as a relatively selective Na(+) channel blocker, also has an inhibitory action on the rapidly-activating delayed-rectifier K(+) current (I(Kr)) through human ether-a-go-go-related gene (hERG) channels. We studied the effects of chronic exposure to pilsicainide on...

Descripción completa

Detalles Bibliográficos
Autores principales: Onohara, Takeshi, Hisatome, Ichiro, Kurata, Yasutaka, Li, Peili, Notsu, Tomomi, Morikawa, Kumi, Otani, Naoyuki, Yoshida, Akio, Iitsuka, Kazuhiko, Kato, Masaru, Miake, Junichiro, Ninomiya, Haruaki, Higaki, Katsumi, Shirayoshi, Yasuaki, Nishihara, Takashi, Itoh, Toshiyuki, Nakamura, Yoshinobu, Nishimura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459418/
https://www.ncbi.nlm.nih.gov/pubmed/28607619
http://dx.doi.org/10.1016/j.joa.2016.09.003
Descripción
Sumario:BACKGROUND: Pilsicainide, classified as a relatively selective Na(+) channel blocker, also has an inhibitory action on the rapidly-activating delayed-rectifier K(+) current (I(Kr)) through human ether-a-go-go-related gene (hERG) channels. We studied the effects of chronic exposure to pilsicainide on the expression of wild-type (WT) hERG proteins and WT-hERG channel currents, as well as on the expression of mutant hERG proteins, in a heterologous expression system. METHODS: HEK293 cells stably expressing WT or mutant hERG proteins were subjected to Western blotting, immunofluorescence microscopy and patch-clamp experiments. RESULTS: Acute exposure to pilsicainide at 0.03–10 μM influenced neither the expression of WT-hERG proteins nor WT-hERG channel currents. Chronic treatment with 0.03–10 μM pilsicainide for 48 h, however, increased the expression of WT-hERG proteins and channel currents in a concentration-dependent manner. Chronic treatment with 3 μM pilsicainide for 48 h delayed degradation of WT-hERG proteins and increased the channels expressed on the plasma membrane. A cell membrane-impermeant pilsicainide derivative did not influence the expression of WT-hERG, indicating that pilsicainide stabilized the protein inside the cell. Pilsicainide did not influence phosphorylation of Akt (protein kinase B) or expression of heat shock protein families such as HSF-1, hsp70 and hsp90. E4031, a chemical chaperone for hERG, abolished the pilsicainide effect on hERG. Chronic treatment with pilsicainide could also increase the protein expression of trafficking-defective mutant hERG, G601S and R752W. CONCLUSIONS: Pilsicainide penetrates the plasma membrane, stabilizes WT-hERG proteins by acting as a chemical chaperone, and enhances WT-hERG channel currents. This mechanism could also be applicable to modulations of certain mutant-hERG proteins.